Peptide Science South Carolina

Peptide Science South Carolina: A Growing Hub of Innovation

Peptide Science South Carolina may not be the first state that comes to mind when thinking about peptide science, but beneath its Southern charm lies a rapidly expanding ecosystem of peptide research, manufacturing, and clinical application. From world-class academic institutions to a burgeoning pharmaceutical manufacturing sector, the Palmetto State is quietly positioning itself as a significant player in the peptide revolution.

Understanding Peptide Science South Carolina

Peptide Science South Carolina are short chains of amino acids—typically consisting of between two and fifty amino acid residues—that serve as the building blocks of proteins and play critical roles in cellular communication, metabolism, and tissue repair. Unlike larger proteins, peptides can be synthesized with relative ease and offer the specificity of biologics with the stability of small molecules. The journal Peptide Science South Carolina, the official publication of the American Peptide Society, publishes significant original research covering all aspects of peptide synthesis, materials, structure, and bioactivity. As the field has matured, peptides have emerged as a promising class of therapeutic agents, effectively bridging the gap between small molecules and large biologics.

Academic Research and Education

South Carolina’s institutions of higher education are actively contributing to the advancement of peptide science through both research and workforce development.

Medical University of South Carolina (MUSC)

The Medical University of South Carolina in Charleston stands at the forefront of peptide-related biomedical research. MUSC researchers have been developing modified peptides as therapeutic agents for fibrotic diseases such as scleroderma, securing patents for peptide-based treatments. The university’s Department of Cell and Molecular Pharmacology and Experimental Therapeutics conducts cutting-edge work in proteomics and peptide identification, including optimizing collagenase-based methods for mass spectrometry imaging of peptides in tissue samples.

MUSC has also been involved in clinical research on glucagon-like peptide-1 (GLP-1) agonists for diabetes treatment. This work places the institution at the intersection of peptide science and clinical translation, contributing to the development of therapies that have captured global attention.

University of South Carolina (USC)

Researchers at the University of South Carolina are exploring the development of novel unnatural peptides for the treatment and prevention of metabolic disorders such as obesity and diabetes. By incorporating unnatural amino acid residues into naturally occurring peptides, these scientists aim to slow enzymatic degradation, thereby extending the peptide’s half-life when taken orally—a critical step toward creating marketable peptide drugs.

The university has also developed a dual-secured therapeutic peptide delivery system featuring a crosslinked polymer network that can incorporate therapeutic peptides for targeted delivery to cancer cells. Additionally, USC is exploring machine learning-engineered peptides for cell osteogenic differentiation, demonstrating the integration of computational approaches with peptide design.

Clemson University

Clemson University researchers are investigating peptoids—synthetic peptide mimics—as a platform for developing applications in medicinal chemistry, materials science, and nanotechnology. Other projects at Clemson involve the encapsulation of antimicrobial peptides to replace antibiotics for infection treatment. The university has also received NSF funding for developing peptide-based nanocarriers for nucleic acid therapeutics.

College of Charleston

At the College of Charleston, Associate Professor Michael Giuliano’s laboratory studies the three-dimensional structure of peptides that carry chemical messages between cells. His work explores how chemists can synthesize peptides outside of living organisms and use spectroscopy to “see” molecules, helping to design new medicines. Students at the college are also engaged in peptide sequencing research with non-canonical residues.

The Manufacturing Sector: AmbioPharm and Beyond

Perhaps the most dramatic evidence of South Carolina’s growing role in peptide science is the expansion of AmbioPharm, a global custom synthetic peptide contract development and manufacturing organization (CDMO) headquartered in North Augusta.

AmbioPharm’s Expansion

Founded in 2005, AmbioPharm specializes in developing highly efficient manufacturing processes for peptide-based active pharmaceutical ingredients (APIs) at scales ranging from small to very large. The company manufactures new chemical entities and peptide APIs under current good manufacturing practice (GMP) regulations for clients worldwide.

In 2026, AmbioPharm announced a $118.96 million expansion of its Aiken County operations, creating 202 new jobs. The expansion includes a 68,000-square-foot modular manufacturing building designed for commercial-scale GMP synthesis, incorporating solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches. Operations are expected to come online by the end of 2027.

The timing reflects surging global demand for peptide therapeutics. As AmbioPharm CEO Brian Gregg noted, “As the global demand for peptide therapeutics accelerates, the need for dependable U.S. manufacturing is extremely important”. While GLP-1 drugs for weight loss and diabetes have captured headlines, Gregg sees broader applications for peptides in oncology, endocrinology, autoimmune diseases, and arthritis. “That boom in peptide drugs is going to continue well beyond obesity,” he said.

Acquisition by CordenPharma

In May 2026, Switzerland-based CordenPharma announced its acquisition of AmbioPharm. The South Carolina facility will become CordenPharma’s second U.S. peptide site, focusing on purification and lyophilization of peptide APIs. The acquisition positions the combined entity to establish a fully U.S.-based peptide supply chain.

Economic Impact

Governor Henry McMaster hailed the expansion as evidence of South Carolina’s advantages in business and manufacturing. Aiken County Council Chairman Gary Bunker noted that the investment “further strengthens Aiken County’s position as a leader in advanced manufacturing and life sciences”. The state has offered incentives including income tax credits worth $1,500 per new job and a 30-year property tax agreement.

Clinical Applications and Peptide Therapy

Beyond research and manufacturing, peptides are making their way into clinical practice across South Carolina.

Wellness and Regenerative Medicine

A growing number of clinics in the Charleston area offer peptide therapy under licensed medical supervision. The Drip Lounge Wellness Center provides personalized peptide therapy designed to support energy levels, recovery, skin quality, and metabolic wellness. Similarly, EVEXIAS Health Solutions offers peptide therapies specifically tailored to women’s health.

Better Life Carolinas in Mount Pleasant provides multiple peptide protocols, including CJC-1295 for sleep and recovery, GHK-Cu for collagen production and skin vitality, Ipamorelin for lean muscle maintenance, and Epithalon for cellular health and healthy aging. Clinics in Greenville and other cities are also incorporating peptide therapy into their wellness offerings.

The Regulatory Landscape

The regulatory environment for peptides remains complex. The FDA regulates peptides based on their intended use—products marketed as dietary supplements, drugs, or for therapeutic purposes require appropriate FDA approvals. Many peptide therapies offered in wellness settings are not FDA-approved, and the agency has increased scrutiny of compounding pharmacies producing peptides for therapeutic use.

However, the landscape may be shifting. South Carolina Public Radio reported in March 2026 that the government could soon lift restrictions on some peptide treatments that have been touted for longevity and wellness. Health Secretary Robert F. Kennedy Jr. has expressed support for moving certain peptides “to a place where people have access from ethical suppliers”. The FDA would need to move these peptides into a category that green-lights production.

Experts caution that many peptides lack evidence from well-controlled human trials. As chemical biologist Eileen Kennedy noted, “There isn’t evidence for a lot of these compounds”. “They haven’t gone through that rigor that’s needed to ultimately know if these will have other off-target effects,” she said.

The Future of Peptide Science South Carolina

South Carolina’s peptide science ecosystem is poised for continued growth. The state’s academic institutions are training the next generation of peptide scientists and conducting foundational research. The manufacturing sector, anchored by AmbioPharm’s expansion, is scaling up to meet global demand. And clinical applications are bringing peptide therapies to patients across the state.

The convergence of these forces—research, manufacturing, and clinical practice—positions South Carolina as an emerging hub in the peptide revolution. As peptide therapeutics continue to expand beyond the GLP-1 spotlight into oncology, autoimmune diseases, and other areas, the Palmetto State’s investments in infrastructure, workforce, and research are likely to pay increasing dividends.

The state’s leadership recognizes this potential. With $119 million in private investment, hundreds of new jobs, and a growing reputation in life sciences, South Carolina is demonstrating that peptide science is not just a coastal phenomenon—it is taking root in the South, one amino acid at a time.